Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Kawabata, Tomoko ^a   Nishida, Keiichiro ^a   Takasugi, Koji ^b   Ogawa, Hiroko ^a   Sada, Kenei ^a   Kadota, Yasutaka ^a   Inagaki, Junko ^a   Hirohata, Satoshi ^a   Ninomiya, Yoshifumi ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Kurashiki Kosai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; HDAC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; MALE; OSTEOARTHRITIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; ADOLESCENT; CELL NUCLEUS; CYTOPLASM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TISSUE CULTURE TECHNIQUE;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; CELL NUCLEUS; CYTOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASE 1; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77954286123     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3071     Document Type: Article

References (48)

1. Mount C, Featherstone J. Rheumatoid arthritis market. Nat Rev Drug Discov 2005, 4:11-12. 10.1038/nrd1611, 15690597.
2. Huber LC, Stanczyk J, Jungel A, Gay S. Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum 2007, 56:3523-3531. 10.1002/art.22948, 17968922.
3. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293:1074-1080. 10.1126/science.1063127, 11498575.
4. Hassig CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1997, 1:300-308. 10.1016/S1367-5931(97)80066-X, 9667866.
5. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998, 20:615-626. 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4≥3.0.CO;2-H, 9780836.
6. Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002, 9:3-16. 10.1016/S1074-5521(02)00092-3, 11841934.
7. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982, 42:65-82.
8. Chang S, Pikaard CS. Transcript profiling in Arabidopsis reveals complex responses to global inhibition of DNA methylation and histone deacetylation. J Biol Chem 2005, 280:796-804.
9. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000, 60:4561-4572.
10. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP, Young BD. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 2003, 39:1165-1175. 10.1016/S0959-8049(03)00072-8, 12736119.
11. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, Gannon F. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005, 24:4894-4907. 10.1038/sj.onc.1208662, 15870696.
12. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, Distler JH, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jungel A. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007, 56:1087-1093. 10.1002/art.22512, 17393417.
13. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 2005, 10:197-204. 10.1016/S1359-6446(04)03309-4, 15708534.
14. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002, 99:2995-3000. 10.1073/pnas.052702999, 122461, 11867742.
15. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003, 8:707-717. 10.1016/S1525-0016(03)00235-1, 14599803.
16. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005, 11:1-15. 10.2119/2006-00005.Dinarello, 1449516, 16557334.
17. Huang N, Katz JP, Martin DR, Wu GD. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 1997, 9:27-36. 10.1006/cyto.1996.0132, 9067093.
18. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 2004, 64:7706-7710. 10.1158/0008-5472.CAN-03-3897, 15520174.
19. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004, 50:3365-3376. 10.1002/art.20709, 15476220.
20. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8:718-728.
21. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23:3912-3922. 10.1200/JCO.2005.02.188, 15851766.
22. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872. 10.1038/sj.bjp.0707165, 2013883, 17325656.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
24. Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue H, Ohmoto Y, Modlin RL, Makino H. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:306-314. 10.1002/1529-0131(199802)41:2<306::AID-ART15≥3.0.CO;2-4, 9485089.
25. Nakamura K, Hirohata S, Murakami T, Miyoshi T, Demircan K, Oohashi T, Ogawa H, Koten K, Toeda K, Kusachi S, Ninomiya Y, Shiratori Y. Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction. J Biochem 2004, 136:439-446. 10.1093/jb/mvh138, 15625312.
26. Yamawaki H, Hirohata S, Miyoshi T, Takahashi K, Ogawa H, Shinohata R, Demircan K, Kusachi S, Yamamoto K, Ninomiya Y. Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology 2009, 19:83-92. 10.1093/glycob/cwn109, 18854367.
27. Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, Apte SS, Ninomiya Y. ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum 2005, 52:1451-1460. 10.1002/art.21010, 15880812.
28. Hatipoglu OF, Hirohata S, Cilek MZ, Ogawa H, Miyoshi T, Obika M, Demircan K, Shinohata R, Kusachi S, Ninomiya Y. ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells. J Biol Chem 2009, 284:16325-16333. 10.1074/jbc.M109.001313, 2713541, 19349275.
29. ImageJ. , http://rsb.info.nih.gov/ij/
30. Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002, 37:458-466. 10.1080/003655202317316105, 11989838.
31. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003, 111:539-552. 151922, 12588892.
32. Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D, Caprilli R. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003, 33:244-248. 10.1046/j.1365-2362.2003.01130.x, 12641543.
33. Grabiec AM, Tak PP, Reedquist KA. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?. Arthritis Res Ther 2008, 10:226. 10.1186/ar2489, 2592777, 18983693.
34. Keslacy S, Tliba O, Baidouri H, Amrani Y. Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol Pharmacol 2007, 71:609-618. 10.1124/mol.106.030171, 17108260.
35. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006, 66:5409-5418. 10.1158/0008-5472.CAN-05-4225, 16707469.
36. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001, 276:44641-44646. 10.1074/jbc.M105170200, 11572859.
37. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J 2002, 21:2672-2681. 10.1093/emboj/21.11.2672, 126040, 12032080.
38. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007, 27:4784-4795. 10.1128/MCB.00494-07, 1951481, 17470557.
39. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 2000, 275:35256-35263. 10.1074/jbc.M003106200, 10938272.
40. Higashitsuji H, Higashitsuji H, Masuda T, Liu Y, Itoh K, Fujita J. Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1. J Biol Chem 2007, 282:13716-13725. 10.1074/jbc.M609751200, 17353187.
41. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009, 36:1580-1589. 10.3899/jrheum.081115, 19531758.
42. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997, 94:10895-10900. 10.1073/pnas.94.20.10895, 23522, 9380731.
43. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002, 99:10025-10030. 10.1073/pnas.152333199, 126618, 12119414.
44. Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, David JR, Bucala R, Morand EF. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003, 48:1881-1889. 10.1002/art.11165, 12847682.
45. Kim MM, Yoon SO, Cho YS, Chung AS. Histone deacetylases, HDAC1 and HSIR2, act as a negative regulator of ageing through p53 in human gingival fibroblast. Mech Ageing Dev 2004, 125:351-357. 10.1016/j.mad.2004.01.010, 15130752.
46. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, Wu CW. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275:20436-20443. 10.1074/jbc.M000202200, 10777477.
47. Taranto E, Xue JR, Lacey D, Hutchinson P, Smith M, Morand EF, Leech M. Detection of the p53 regulator murine double-minute protein 2 in rheumatoid arthritis. J Rheumatol 2005, 32:424-429.
48. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J 2002, 21:6236-6245. 10.1093/emboj/cdf616, 137207, 12426395.